Ridgeback Group Reports 6.25M Shares in Replimune (REPL)
Ridgeback Group reported a 7.6% beneficial ownership stake in Replimune Group, Inc. (REPL), totaling 6,252,651 shares. This disclosure was made through a Schedule 13G SEC filing, indicating a passive investment intent. The ownership percentage is based on Replimune's 82,572,619 shares outstanding as of January 30, 2026.
Replimune Group stock (US76029N1063): insider selling and legal probe put focus on biotech story
Replimune Group is facing increased scrutiny due to recent insider share sales and a securities law investigation, even as the company continues to advance its oncolytic immunotherapy pipeline. The Nasdaq-listed biotechnology firm specializes in developing herpes simplex virus-based therapies for cancer. Investors are closely monitoring clinical trial progress, funding strategies, and the potential impact of the legal probe on the company's future.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
Pomerantz LLP is investigating Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors for potential securities fraud and unlawful business practices. This investigation follows a significant 64.29% stock price drop after Replimune received a Complete Response Letter from the FDA regarding its Biologics License Application for RP1, citing disagreements over data sufficiency. Investors are encouraged to contact Pomerantz LLP to inquire about joining a potential class action.
Replimune group CAO sells $40,101 in common stock By Investing.com
Replimune Group's Chief Accounting Officer, Andrew Schwendenman, sold 7,894 shares of common stock for a total of $40,101. This "sell to cover" transaction was to meet tax obligations from RSU vesting, not a discretionary sale. The company's stock has faced significant declines and regulatory setbacks, including an FDA Complete Response Letter for its lead product candidate, RP1, though recent political events led to temporary stock surges.
Replimune group CAO sells $40,101 in common stock
Replimune Group's Chief Accounting Officer, Andrew Schwendenman, sold 7,894 shares of common stock for $40,101 to cover tax withholding obligations on May 18, 2026. This transaction was not a discretionary sale. The company has recently faced significant challenges including an FDA Complete Response Letter for its lead product and subsequent analyst downgrades, though its stock saw temporary surges related to political news.
[Form 4] Replimune Group, Inc. Insider Trading Activity
Replimune Group, Inc.'s CEO, Sushil Patel, reported selling 37,324 shares of common stock at a weighted average price of $5.08 per share. This sale was non-discretionary and exclusively to cover tax withholding obligations related to the partial vesting of his Restricted Stock Units. Following this transaction, Patel directly holds 747,492 shares of Replimune common stock.
[Form 4] Replimune Group, Inc. Insider Trading Activity
Replimune Group, Inc.'s Chief Medical Officer, Konstantinos Xynos, reported an open-market sale of 14,023 shares of common stock on May 18, 2026, at a weighted average price of $5.08 per share. This transaction was a "sell to cover" to meet tax withholding obligations from vesting Restricted Stock Units and was not a discretionary sale. Following this sale, Xynos directly holds 235,662 shares.
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors for potential securities law violations. This investigation follows a significant drop in Replimune's stock price by almost 64.3% after the company received a complete response letter from the FDA for its Biologics License Application for RP1. The firm encourages affected shareholders to contact them to discuss their legal rights.
RTW Investments, R. Wong report 7.36M shares in Replimune (NASDAQ: REPL)
RTW Investments, LP and Roderick Wong have reported beneficial ownership of 7,356,916 shares of Replimune Group, Inc. (NASDAQ: REPL), representing 8.9% of the company's outstanding common stock. This disclosure was made via a Schedule 13G/A filing, indicating a passive investment. Both RTW Investments and Roderick Wong share voting and dispositive power over these shares, which were calculated based on 82,572,619 shares outstanding as of January 30, 2026.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
Pomerantz LLP is investigating Replimune Group, Inc. (NASDAQ: REPL) for potential securities fraud after the company received a complete response letter (CRL) from the FDA regarding its Biologics License Application for RP1. The FDA cited disagreement over the sufficiency of the data set, causing Replimune's stock price to fall significantly by 64.29%. Investors are encouraged to contact Pomerantz LLP for information about potentially joining a class action lawsuit.
Micron Rallied 90% In A Month — These 10 Small‑Cap Stocks Blew Past It
While Micron Technology saw a 90% rally in a month, largely attributed to the AI memory cycle, ten small-cap stocks from the Russell 2000 index significantly outperformed it, with returns exceeding 110% over the past 30 days. Many of these top-performing small-cap companies are benefiting from the AI infrastructure boom, delivering strong first-quarter earnings and raising their guidance. Their success highlights investment opportunities beyond large-cap tech in the current market climate.
Replimune surges day after FDA Commissioner Makary resigns
Replimune Group (REPL) stock surged approximately 30% on Wednesday, following the resignation of FDA Commissioner Marty Makary. Replimune had been critical of the FDA regarding its application for a melanoma treatment. Makary's departure occurred amidst reports of pressure from the President.
Replimune Group Stock Short Interest Rises to 50.44%
Replimune Group's (NASDAQ:REPL) short interest increased by 50.44% in April, reaching 8,430,000 shares. This corresponds to 24.3 days to cover on average daily volume. A higher short interest can sometimes precede a short squeeze, indicating negative sentiment among some investors.
[SCHEDULE 13G] Replimune Group, Inc. Passive Investment Disclosure (>5%)
Suvretta Capital Management, LLC and Aaron Cowen have filed a Schedule 13G for Replimune Group, Inc. (REPL), reporting beneficial ownership of 4,221,836 shares each, representing 5.1% of the common stock. The filing indicates shared voting and dispositive power over these shares, which are held for advisory clients, and disclaims beneficial ownership except for pecuniary interest. This disclosure signals an institutional investment rather than direct sole control, with no immediate indications of strategic engagement or supply pressure.
Replimune Group stock (US76029N1063): FDA rejection of RP1 melanoma therapy draws backlash
Replimune Group's lead therapy, RP1 for melanoma treatment, was recently rejected by the FDA, leading to significant industry criticism and a drop in the company's stock price. Reports suggest potential leadership changes at the FDA following the decision. Despite the setback, analysts forecast a target price of $4.75 for Replimune shares, which closed at $3.73 after an 8.35% decline.
Replimune Group Stock Short Interest Rises to 50.44%
Replimune Group's (NASDAQ: REPL) short interest surged to 50.44% of its float as of April 30th, an increase of 14.83% from mid-April, indicating a significant bearish sentiment. This comes amid varied hedge fund activity, with some major increases and decreases in institutional holdings, and consistent insider selling over the past six months. Additionally, recent analyst ratings include two "Sell" recommendations and a median price target of $2.0 from four analysts.
Number of shareholders of Replimune Group, Inc. – LSX:A2JQN1
This article focuses on the number of shareholders for Replimune Group, Inc., trading under the symbol A2JQN1 on the Lang & Schwarz Exchange. It highlights the company's financial overview within the health technology and biotechnology sectors, accessible through TradingView. The page provides market data from ICE Data Services and reference data from FactSet, along with SEC filings from Quartr.
REPL Soars As Trump FDA Shake-Up Revives RP1 Hopes
Replimune Group Inc. (REPL) stock surged by 27.36% due to renewed investor optimism following positive trial news and political pressure on the FDA regarding its RP1 melanoma drug. Despite being a pre-commercial, clinical-stage oncology company with negative profitability, its strong cash position and working capital provide a solid runway. Technically, the stock broke out from consolidation, indicating a short-term bullish trend driven by reassessed regulatory risk and potential for RP1 reconsideration.
REPL Stock Jumps As Wall Street Journal Challenges FDA
Replimune Group Inc. (REPL) stock jumped over 21% following a Wall Street Journal editorial that criticized the FDA's rejection of its RP1 melanoma therapy. The editorial highlighted that the FDA did not deem RP1 ineffective, shifting trader sentiment from capitulation to speculation despite the company's significant quarterly losses. This media challenge created a short-term catalyst, emphasizing a regulatory dispute rather than scientific failure, and driving momentum for the stock.
How many employees work at Replimune Group?
Replimune Group, Inc. has 455 employees as of December 2025, according to Revelio Labs. The company aims to revolutionize cancer treatment with oncolytic immunotherapies. Their workforce has shown consistent growth, with 455 employees in 2025 representing a 6.5% increase from the previous year.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
Pomerantz LLP has launched an investigation into Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors, probing potential securities fraud or unlawful business practices. This follows Replimune's announcement on April 10, 2026, that it received a complete response letter from the FDA regarding its Biologics License Application for RP1, leading to a significant 64.29% drop in its stock price. Investors affected by this news are encouraged to contact the law firm.
MA Biotech Downgraded to Neutral After Second FDA CRL for RP1 Melanoma BLA
Wedbush Securities downgraded Replimune Group Inc. (NASDAQ:REPL) to Neutral from Outperform and slashed its price target to US$2.00 from US$19.00 following a second Complete Response Letter (CRL) from the FDA for its RP1 Biologics License Application (BLA) in PD-1 refractory melanoma. The FDA cited deficiencies including an inability to isolate RP1's contribution, study population heterogeneity, and concerns about response assessments in the single-arm Phase 2 IGNYTE trial. Despite Replimune's arguments regarding inconsistencies with FDA feedback and strong treatment effect, Wedbush sees no clear path forward for RP1 with IGNYTE, leading to significant downside risk for the company.
What's Going On With Replimune Stock On Tuesday?
Replimune Inc. (REPL) stock is experiencing significant weakness due to mounting criticism surrounding FDA leadership and its drug approval decisions, particularly affecting Replimune's melanoma treatment. FDA Commissioner Marty Makary defended the agency's decisions, stating three independent review teams reached the same conclusion regarding Replimune's drug. The controversy has led to a notable decline in REPL's stock price.
REPL Stock Plunges As FDA Rejects Key Melanoma Therapy
Replimune Group Inc. (REPL) stock plunged significantly after the FDA issued a Complete Response Letter rejecting its Biologics License Application (BLA) for RP1 in combination with nivolumab for advanced melanoma, citing insufficient trial data. This rejection led to multiple analyst downgrades, legal investigations into potential securities fraud, and the company's decision to scale back the RP1 program, cut jobs, and reduce U.S. manufacturing. REPL now trades near its book value, creating a volatile, high-risk scenario for active traders due to regulatory uncertainty, legal overhang, and a wounded flagship product.
What's Going On With Replimune Stock On Tuesday?
Replimune Group (NASDAQ: REPL) stock showed significant weakness on Tuesday following criticism surrounding FDA Commissioner Marty Makary's leadership and the agency's drug approval processes. The FDA's rejection of Replimune's melanoma treatment, despite promising patient outcomes, is a central point of contention. Makary defended the FDA's scientists and decisions, stating that three independent review teams reached the same conclusion regarding the drug.
Short Interest in Replimune Group, Inc. (NASDAQ:REPL) Grows By 12.8%
Short interest in Replimune Group, Inc. (NASDAQ:REPL) increased by 12.8% in April, reaching 18.43 million shares, which represents 23.5% of its shares sold short and a short-interest ratio of 1.4 days. Several analysts have downgraded the stock and lowered price targets, resulting in a "Reduce" consensus rating and an average target price of $4.75. Insider Christopher Sarchi also sold 6,500 shares, reducing his ownership by 4.11%, while institutional investors continue to hold a significant stake of 92.53%.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
Pomerantz LLP is investigating Replimune Group, Inc. (REPL) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows a significant stock price drop after the FDA issued a complete response letter for Replimune's Biologics License Application for RP1, citing a disagreement on data sufficiency. Investors are encouraged to contact the firm for more information.
Replimune Group, Inc. (REPL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group, Inc. (NASDAQ:REPL) securities. This investigation follows a significant stock price drop after Replimune received a complete response letter from the FDA for its Biologics License Application for RP1, citing disagreement over the sufficiency of the data. Investors are encouraged to contact the firm to learn more about participating in the investigation.
Replimune Group (REPL) price target decreased by 59.94% to 5.04
This article reports a significant 59.94% decrease in the price target for Replimune Group (REPL), bringing it down to $5.04. The change in price target suggests a revised outlook on the company's future performance or valuation. However, no further details or reasons for this substantial reduction are provided.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group, Inc. (REPL) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Replimune Group, Inc. (REPL) on behalf of investors who purchased the company's securities. This investigation follows a significant stock price drop after Replimune received a complete response letter from the FDA for its Biologics License Application for RP1, citing disagreements over the sufficiency of supporting data. The firm encourages affected shareholders to connect and assist in the investigation at no cost.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
Pomerantz LLP is investigating Replimune Group, Inc. (NASDAQ: REPL) on behalf of investors following a significant stock price drop. The investigation stems from Replimune receiving a complete response letter (CRL) from the FDA regarding its Biologics License Application for RP1, citing a disagreement over data sufficiency. Replimune's stock subsequently fell by 64.29% to $1.70 per share on April 13, 2026.
Replimune brings 3-year melanoma survival data to ASCO oral session
Replimune (NASDAQ: REPL) is scheduled to present multiple clinical updates at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including two oral abstracts and four poster presentations. Key presentations will cover 3-year overall survival data for RP1 plus nivolumab in advanced melanoma and final Phase 1 results for RP2. This announcement has led to a moderate positive market reaction, with REPL stock gaining 2.27% following the news.
Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, Inc. (REPL) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims on behalf of purchasers of Replimune Group, Inc. (NASDAQ: REPL) after the company received a complete response letter from the FDA regarding its Biologics License Application for RP1. This news led to a significant 64.29% drop in Replimune's stock price. The firm is encouraging affected investors to inquire about the investigation.
Bronstein, Gewirtz & Grossman, LLC Encourages Replimune Group, Inc. (REPL) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Replimune Group, Inc. (REPL) stockholders following a significant stock price drop. This drop occurred after Replimune received a Complete Response Letter from the FDA for its Biologics License Application for RP1, citing disagreement over data sufficiency. The firm encourages affected investors to inquire about the securities investigation.
REPL Stock Crashes As FDA Rejects RP1 Melanoma Bid Again
Replimune Group Inc. (REPL) stock crashed by over 60% after the FDA issued a second Complete Response Letter for its BLA for RP1 in melanoma, effectively rejecting the drug. This led to widespread analyst downgrades and a significant decline in the stock's value, with legal investigations also being launched into potential securities-law violations. The company's future for RP1 in melanoma is uncertain, turning REPL into a distressed oncology name.
REPL Stock Collapses As FDA Rejects RP1 Melanoma Bid
Replimune Group Inc. (REPL) stock plunged over 60% after the FDA rejected its Biologics License Application (BLA) for RP1 plus nivolumab in anti-PD-1–failed melanoma. This decision led to broad analyst downgrades and significant price target cuts, highlighting the company's compromised lead asset and unclear strategic path. Concerns about weak fundamentals, high cash burn, and emerging securities-law investigations add further pressure, making REPL a speculative option on its residual pipeline.
Replimune Group Stock Short Interest Rises to 43.93%
Replimune Group (REPL) saw its short interest increase to 43.93% of the float as of April 15th, representing a 12.8% rise from March 31st. Hedge funds showed mixed activity, with some significantly adding to their positions while others drastically reduced theirs. Insiders, on the other hand, have primarily engaged in selling shares over the past six months, with no recorded purchases.
Replimune Group (NASDAQ:REPL) Cut to "Strong Sell" at Wall Street Zen
Wall Street Zen has downgraded Replimune Group (NASDAQ:REPL) from "sell" to "strong sell," reflecting a broader bearish sentiment among analysts, with a consensus rating of "Reduce" and a target price of $4.75. The stock opened at $2.42, trading down 15.1% and near its 52-week low amid forecasts for a negative EPS. Insider selling and high institutional ownership are also noted in the article.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Replimune Group, Inc. (REPL) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Replimune Group, Inc. (REPL) following a significant drop in its stock price. This occurred after Replimune received a Complete Response Letter from the FDA regarding its Biologics License Application for RP1, citing disagreements over data sufficiency. The firm encourages investors who purchased Replimune securities to join the investigation.
REPL Stock Collapses As FDA Rejection Triggers Downgrades And Probes
Replimune Group Inc. (REPL) stock plummeted nearly 64% after the FDA issued a Complete Response Letter for its lead therapy, RP1 plus nivolumab, citing inadequate evidence of effectiveness. This rejection triggered multiple analyst downgrades and price target cuts, with some firms reducing targets to $1-$2. The company announced job cuts and scaled back U.S. manufacturing, and a law firm launched a securities-fraud investigation, turning REPL into a highly volatile, headline-driven stock.
200+ Mass. biotech employees were laid off last week. That may only be the beginning
Replimune Group Inc., a Woburn-based biotechnology company, laid off 224 employees last week after the FDA rejected its lead cancer drug, RP1, for the second time. These significant cuts, representing nearly half of the company's workforce, primarily impacted commercial, manufacturing, and R&D divisions in Woburn and Framingham. The company's filings also suggest that more layoffs may be imminent as Replimune explores strategic alternatives.
Replimune Group, Inc. (REPL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Replimune Group, Inc. (REPL) following a significant drop in its stock price. This decline occurred after the U.S. Food and Drug Administration (FDA) issued a complete response letter for Replimune's Biologics License Application for RP1, citing disagreements over the sufficiency of the supporting data. The law firm is encouraging shareholders who purchased Replimune securities to contact them to learn more about the investigation into potential claims.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group, Inc. (REPL) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group, Inc. (REPL) after a significant stock drop. The investigation follows Replimune receiving a complete response letter from the FDA for its Biologics License Application for RP1, citing a disagreement over the sufficiency of data. Investors who purchased Replimune securities are encouraged to contact the firm to assist with the investigation.
Mass. biotech company facing between 161 and 224 layoffs after FDA rejects drug for 2nd time
Replimune Group, Inc., a Woburn biotechnology company, is facing 161 to 224 layoffs after the FDA rejected its lead cancer treatment, RP1, for the second time. The rejections were due to concerns about the adequacy of the IGNYTE clinical trial, despite promising patient response rates. The company is now exploring strategic alternatives following the substantial job cuts across its Massachusetts facilities.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group, Inc. (REPL) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Replimune Group, Inc. (REPL) securities. This investigation follows a significant stock price drop after Replimune received a complete response letter from the FDA for its Biologics License Application for RP1, citing disagreement over data sufficiency. The firm is encouraging affected stockholders to connect to assist with the investigation.
Why Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma Application And What's Next
Replimune Group's stock plunged 75.0% after the FDA issued a complete response letter rejecting its Biologics License Application for RP1 plus nivolumab in advanced melanoma. The company cites inconsistent FDA processes, while analysts highlight the intensified regulatory uncertainty, cash runway concerns, and potential shareholder dilution. The investment narrative for Replimune now heavily depends on the outcome and pace of its IGNYTE-3 trial and future funding capacities.
Replimune Group FY2026 EPS Estimate Lifted by HC Wainwright
HC Wainwright has revised its FY2026 EPS estimate for Replimune Group (NASDAQ:REPL) to ($3.35) from ($3.46), maintaining a "Sell" rating. This adjustment comes amidst a consensus analyst stance of "Reduce" with an average price target of $4.75, following the FDA's Complete Response Letter (CRL) for the company's lead candidate RP1 and reports of planned workforce reductions. Despite a brief 14.7% surge in share price to $1.95, the stock remains highly volatile with a market cap of $161 million.
FDA Rejection Sparks Questions On Replimune Drug Approval Path
Replimune received a Complete Response Letter from the FDA for its drug RP1, sparking controversy as the company cited inconsistencies in the review process and prior FDA feedback. Several analysts subsequently downgraded Replimune's stock, reflecting concerns about a significantly longer and uncertain approval path for RP1. The company's shares plunged over 63% following the announcement.
Replimune Group (REPL) Is Down 75.0% After FDA Rejects RP1 Melanoma BLA Over Trial Design Concerns
Replimune Group's shares plummeted 75.0% after the FDA rejected its Biologics License Application (BLA) for RP1 plus nivolumab for advanced melanoma, citing trial design concerns despite earlier breakthrough therapy designation. This decision has significantly heightened uncertainty regarding approval timelines and funding, as the company faces substantial losses and limited cash flow. Investors now face a higher risk profile, with opinions on the company's fair value diverging widely.
REPL Slides After Insider Filings Spark Trader Caution
Replimune Group Inc. (REPL) stocks have experienced a significant slide, dropping from the $7-$8 range to below $2 in less than two weeks, despite an initial 13.82% surge. This volatility is largely attributed to a cluster of Form 4 insider filings on April 7, 2026, which reported changes in beneficial ownership but lacked crucial details such as whether the transactions were buys or sells, their size, or context. Traders are now treating REPL as a high-risk, high-volatility biotech stock, with experts advising caution and urging monitoring for future, more transparent filings rather than using the current vague filings as a trading trigger.
